Freya Biosciences
PrivateLast Round
Series A
Extension
Nov 19, 2024
Total Funding Raised
$57.8M
Company Overview
Freya Biosciences operates in Healthcare & Life Sciences and is based in Copenhagen. Its latest recorded funding round was a Series A Extension round in November 2024.
Freya Biosciences is a biotechnology company developing microbial immunotherapies to address immune drivers of reproductive health conditions in women.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Freya Biosciences Comparables
Compare Freya Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vaginal Biome Science | 81% | |
| Osel Inc. | 78% | |
| Gedea Biotech | 72% |
For institutional investors. Book with your work email.
Freya Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 19, 2024 | ||||
| Series A | Dec 12, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Freya Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OMX Ventures | Series A |
| Indaco Venture Partners SGR | Series A |
| Corundum Systems Biology | Series A |
| Bill & Melinda Gates Foundation | Series A Extension |
| The Bill & Melinda Gates Foundation Trust | Series A Extension |
| Angelini Ventures | Series A |
| The Export and Investment Fund of Denmark | Series A Extension, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 19, 2024
$12M round led by Bill & Melinda Gates Foundation.
- Dec 12, 2023
$38M round led by OMX Ventures and Sofinnova Partners.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asOct 5, 2026
On Oct 5th '26 in Denmark and the United States, Fierce Biotech, a division of Forge, named Freya Biosciences one of 2026's Fierce 15 biotechnology companies, recognizing it as one of the industry's most innovative and promising private biotechnology companies.
- recognized_asOct 5, 2026
Fierce Biotech named Freya Biosciences one of its “Fierce 15” private biotechs in Oct '26, recognizing the company among 15 biotechs selected for the strength of their science and potential to shape next-generation medicines.
- recognized_asOct 5, 2026
On Oct 5th '26, Fierce Biotech, a division of Forge, named Freya Biosciences one of 2026's Fierce 15 biotechnology companies in Denmark and Massachusetts, recognizing it as one of the industry's most innovative and promising private biotechnology companies.
- is_developingOct 5, 2026
Freya Biosciences is a clinical-stage immunology company developing disease-modifying therapies for women’s health conditions involving inflammation and immune dysregulation, including therapies for IVF-related embryo implantation failure and preterm birth.
For institutional investors. Book with your work email.
Freya Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Freya Biosciences's valuation, stock price, and market status.
Is Freya Biosciences a public or private company?
Freya Biosciences is a private company.
What is the current stock price of Freya Biosciences?
Freya Biosciences is a private company, so its shares have no public market price. Caplight tracks Freya Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Freya Biosciences worth (valuation)?
Valuation information for Freya Biosciences is not publicly available.
Can I buy Freya Biosciences stock?
Freya Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Freya Biosciences's last funding round?
Freya Biosciences's most recent funding round was Series A Extension on November 19, 2024.
Who are the main investors in Freya Biosciences?
Key investors in Freya Biosciences include OMX Ventures, Bill & Melinda Gates Foundation, The Bill & Melinda Gates Foundation Trust, Sofinnova Partners, OMX Ventures.
Will Freya Biosciences IPO soon?
No public IPO plans have been announced for Freya Biosciences.
How can I track Freya Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Freya Biosciences's shares on secondary markets.